Preliminary observations on L-dopa in the treatment of Parkinson's disease.
D000284:Administration, Oral; D000328:Adult; D000367:Age Factors; D000368:Aged; D001219:Aspartate Aminotransferases / Q000097:blood; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use* / Q000633:toxicity; D004361:Drug Tolerance; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007022:Hypotension / Q000139:chemically induced; D007275:Injections, Intravenous; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D011379:Prognosis
D004295:Dihydroxyphenylalanine; D001219:Aspartate Aminotransferases